NBENnebag ag
6.600CHF+0.76%Mkt Cap: 68.76M $P/E: 18.86

nebag ag is a publicly owned investment manager. The firm provides its services to Institutional and private investors. It invests in in Switzerland or in neighboring countries. nebag ag is based in Zurich, Switzerland.

HeadlineSourceTime
This week
schweizeraktien.net
Older
finanzen.ch
TradingView
MarketScreener Schweiz
boerse.de
boerse.de
boerse.de
Shareholders in nebag ag (VTX:NBEN) are in the red if they invested five years ago

For many, the main point of investing is to generate higher returns than the overall market. But every investor is...

Simply Wall St.
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters